Expression of miR-486 is a potential prognostic factor after nephrectomy in advanced renal cell carcinoma

Goto,Keisuke; Oue,Naohide; Shinmei,Shunsuke; Sentani,Kazuhiro; Sakamoto,Naoya; Naito,Yutaka; Hayashi,Tetsutaro; Teishima,Jun; Matsubara,Akio; Yasui,Wataru

doi:10.3892/mco.2012.46

Expression of miR-486 is a potential prognostic factor after nephrectomy in advanced renal cell carcinoma

Authors:
- Keisuke Goto
- Naohide Oue
- Shunsuke Shinmei
- Kazuhiro Sentani
- Naoya Sakamoto
- Yutaka Naito
- Tetsutaro Hayashi
- Jun Teishima
- Akio Matsubara
- Wataru Yasui
View Affiliations

Affiliations: Department of Molecular Pathology, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima 734-8551, Japan, Department of Urology, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima 734-8551, Japan
Published online on: November 27, 2012 https://doi.org/10.3892/mco.2012.46
Pages: 235-240

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Renal cell carcinoma is the most frequently occurring neoplasm in the adult kidney, leading to poor prognosis. Therefore novel biomarkers are required for the prediction of early metastasis following nephrectomy. The aim of the present study was to investigate whether or not expression levels of miR‑486, detected in RNA isolated from formalin‑fixed paraffin‑embedded tissue sections, can predict prognosis for patients with renal cell carcinoma (RCC). Expression levels of miR‑486 were measured by quantitative reverse transcriptase‑polymerase chain reaction in 150 RCC cases. Expression of miR‑486 in RCC samples was ~2.7-fold higher than in corresponding non‑neoplastic kidney samples (P<0.0001). In stage III and IV RCC cases (n=46), a high miR‑486 expression in tumors was associated with worse cancer‑specific mortality, independent of clinical covariates, including TNM staging (P=0.0064). In addition, miR‑486 expression tended to be associated with cancer‑specific mortality in stage III and IV RCC patients who were not treated with interferon‑α (Kaplan‑Meier analysis, n=14, P=0.0574). These results suggest that miR‑486 is a promising biomarker to identify poor prognosis in RCC patients. As expression of miR‑486 was measured from formalin‑fixed paraffin‑embedded (FFPE) samples, this study demonstrated that measurement of miR‑486 may be readily translated into clinical applications.

View Figures

View References

1	Srinivasan M, Sedmak D and Jewell S: Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol. 161:1961–1971. 2002. View Article : Google Scholar : PubMed/NCBI
2	Specht K, Richter T, Muller U, Walch A, Werner M and Hofler H: Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol. 158:419–429. 2001. View Article : Google Scholar : PubMed/NCBI
3	Huntzinger E and Izaurralde E: Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet. 12:99–110. 2011. View Article : Google Scholar : PubMed/NCBI
4	Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
5	Schetter AJ, Heegaard NH and Harris CC: Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis. 31:37–49. 2010. View Article : Google Scholar : PubMed/NCBI
6	Ueda T, Volinia S, Okumura H, et al: Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 11:136–146. 2010. View Article : Google Scholar : PubMed/NCBI
7	Gottardo F, Liu CG, Ferracin M, et al: Micro-RNA profiling in kidney and bladder cancers. Urol Oncol. 25:387–392. 2007. View Article : Google Scholar : PubMed/NCBI
8	White NM, Bao TT, Grigull J, et al: miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. J Urol. 186:1077–1083. 2011. View Article : Google Scholar : PubMed/NCBI
9	Narducci MG, Arcelli D, Picchio MC, et al: MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sézary syndrome. Cell Death Dis. 2:e1512011.PubMed/NCBI
10	Hu Z, Chen X, Zhao Y, et al: Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 28:1721–1726. 2010. View Article : Google Scholar : PubMed/NCBI
11	Konishi H, Ichikawa D, Komatsu S, et al: Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma. Br J Cancer. 106:740–747. 2012. View Article : Google Scholar : PubMed/NCBI
12	Small EM, O’Rourke JR, Moresi V, et al: Regulation of PI3-kinase/Akt signaling by muscle-enriched microRNA-486. Proc Natl Acad Sci USA. 107:4218–4223. 2010. View Article : Google Scholar : PubMed/NCBI
13	Crackower MA, Oudit GY, Kozieradzki I, et al: Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell. 110:737–749. 2002. View Article : Google Scholar : PubMed/NCBI
14	Oh HK, Tan AL, Das K, et al: Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer. Clin Cancer Res. 17:2657–2667. 2011. View Article : Google Scholar : PubMed/NCBI
15	Medical Research Council Renal Cancer Collaborators: Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators Lancet. 353:14–17. 1999.
16	Oue N, Sentani K, Noguchi T, et al: Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients. Int J Cancer. 125:2383–2392. 2009. View Article : Google Scholar : PubMed/NCBI
17	Koshida S, Kobayashi D, Moriai R, Tsuji N and Watanabe N: Specific overexpression of OLFM4(GW112/HGC-1) mRNA in colon, breast and lung cancer tissues detected using quantitative analysis. Cancer Sci. 98:315–320. 2007. View Article : Google Scholar : PubMed/NCBI
18	Liu W, Liu Y, Zhu J, Wright E, Ding I and Rodgers GP: Reduced hGC-1 protein expression is associated with malignant progression of colon carcinoma. Clin Cancer Res. 14:1041–1049. 2008. View Article : Google Scholar : PubMed/NCBI